Compare Incyte Corporation (INCY) vs iShares MBS ETF (MBB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs iShares MBS ETF — how do they compare? Incyte Corporation trades at $112.82 (market cap $22.85B), while iShares MBS ETF trades at $89.52 (market cap $35.41B). The key difference: iShares MBS ETF is the larger of the two by market cap, and Incyte Corporation is trading nearer its 52-week high, iShares MBS ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Incyte Corporation for 33 Days and iShares MBS ETF for 96 Days on average.
| INCY | MBB | |
|---|---|---|
Market Cap | $22.85B | $35.41B |
Volume | 1,927,029 | 5,388,525 |
Sector | Health | Fixed Income |
52-Week High | $129.93 | $96.91 |
52-Week Low | $83.80 | $89.09 |
Typical Hold Time | 33 Days | 96 Days |
Enterprise Value | $18.35B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte (INCY) trades at $113.44, up 0.63% with a bullish technical signal despite mixed moving averages. The company shows strong fundamentals with 2025 revenue of $5.14B, net income of $1.29B, and impressive profitability margins (gross margin 92.62%, net margin 27.71%). Recent FDA approval for Atebrioz and pipeline expansion signal growth beyond JAKAFI. Valuation appears reasonable with P/E of 14.36 and P/S of 3.98.
Outlook remains positive with analyst consensus target of $132.43 (16.7% upside) and 52% buy ratings. Key opportunities include pipeline diversification and $4B sales target, while risks involve JAKAFI patent expiration post-2029 and competitive pressures. Strong cash flow generation ($1.41B operating CF) supports continued R&D investment.
MBB, the iShares MBS ETF, trades at $89.54, up 0.36% on the day but showing a bearish technical signal overall. The ETF has faced significant short interest growth of 98.3% in September 2026, reaching 6.57 million shares, and recently hit a 52-week low. Recent news highlights concerns over intermediate duration risk amid potential rate hikes, though institutional buying from firms like Corient Private Wealth and Baird Financial Group provides some support. Key technical indicators show oversold conditions on the 12-day RSI but strong selling pressure from moving averages.
The outlook for MBB remains cautious due to interest rate sensitivity and convexity risks in the mortgage-backed securities market. While dividend payments offer income, rising rates and inflation pressures pose downside risks. Analyst sentiment is neutral to bearish, with the ETF's performance heavily tied to Federal Reserve policy. Investors should weigh the high yield against duration risk in a tightening cycle.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About iShares MBS ETF
The fund will invest at least 80% of its assets in the component securities of the underlying index and TBAs that have economic characteristics that are substantially identical to the economic characteristics of the component securities of the index, and the fund will invest at least 90% of its assets in fixed income securities included in the underlying index that advisor believes will help the fund track the index.
Read more on MBB →
